Johnson & Johnson to acquire Halda Therapeutics for $3.05bn.

Johnson & Johnson, a company which engages in the research and development, and manufacture and sale of products in the health care field, agreed to acquire Halda Therapeutics, a clinical-stage biotechnology company with a proprietary platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05bn. “This acquisition further strengthens our deep oncology pipeline with an exciting lead asset in prostate cancer and a platform capable of treating multiple cancers and diseases beyond oncology, providing a potential mid- and long-term catalyst for growth. We look forward to combining Halda’s pipeline, platform and people with our world class R&D, commercial and manufacturing capabilities and advancing our goal of bringing these therapies to patients around the world,” Jennifer Taubert, Johnson & Johnson Executive Vice President and Worldwide Chairman.